The fact
The company pursues multiple therapeutic fronts including HIV, rheumatoid arthritis, Ebola and hepatocellular carcinoma with safety data forthcoming.
The market anticipates major announcements regarding product license renewals such as Imurel, supporting the stock's upward trajectory.
Click the link to read an article on the topic: